AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker
Axicabtagene Ciloleucel Cell Therapy Release Quality Checker
ADC Advanced therapy Biopharma BiopharmaExtended Bispecific CSV→JSON CellTherapy FDC
Open selectionAxicabtagene Ciloleucel Cell Therapy Release Quality Checker — CAR-T Therapy Release Control
ℹ️ Utility checks critical parameters for CAR-T therapy product release:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive Cells: ≥50%
• CD3+ Cells: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number (VCN): ≤10
⚠️ CRITICAL: This is a live autologous product. Contamination or low viability is unacceptable.
Low level of CAR-positive cells reduces therapy efficacy.
Usage:
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe → demo mode
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe input.csv output.json → evaluate data
Input format:
BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber
Example (0=Neg, 1=Pos):
AXI-CTL-2026-001,85.0,4.5,65.0,95.0,1.8,2.5,0,0,3.2
— WHY IS THIS NEEDED?
Axicabtagene ciloleucel (Yescarta) is an autologous CAR-T immunotherapy for lymphoma:
• Patient's T-cells are modified with Chimeric Antigen Receptor (CAR)
• Targets CD19 antigen on tumor B-cells
• Manufacturing process is individual for each patient
• Requires strict control of viability, potency, and safety
⚠️ CRITICAL:
• Viability ≥70% — necessary for cell survival after infusion
• Dose 2–10 x 10^6 cells/kg — therapeutic window
• CAR Positive ≥50% — indicator of successful transduction and potency
• CD3+ ≥90% — confirmation of T-cell identity
• CD4/CD8 Ratio — balance of immune response
• Endotoxin ≤5 EU/mL — safety for IV administration
• Mycoplasma/Sterility — absence of contamination is mandatory
• VCN ≤10 — limitation of genotoxicity risk (insertional mutagenesis)
Key features:
• Potency assessment via CAR-positive cell percentage
• Identity (CD3+) and subset (CD4/CD8) control
• Strict microbiological criteria for live cell product
• Genetic modification safety assessment (VCN)
Critical parameters:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive: ≥50%
• CD3 Positive: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number: ≤10 copies/cell
💡 Usage tips:
1. Viability determined by flow cytometry or automated counter
2. CAR expression measured using specific anti-CAR antibodies
3. VCN determined by qPCR
4. Sterility and mycoplasma tests may take several days (rapid methods used for release)
5. Product stored cryopreserved until thawing at bedside
6. Any deviation in sterility leads to immediate batch destruction
⚠️ Note: Unlike traditional drugs, each batch is unique (autologous product). Release criteria are adapted to individual patient characteristics (dose per kg body weight). Safety is the absolute priority due to risk of cytokine release syndrome and neurotoxicity, which can be exacerbated by impurities or contamination.
ℹ️ Utility checks critical parameters for CAR-T therapy product release:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive Cells: ≥50%
• CD3+ Cells: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number (VCN): ≤10
⚠️ CRITICAL: This is a live autologous product. Contamination or low viability is unacceptable.
Low level of CAR-positive cells reduces therapy efficacy.
Usage:
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe → demo mode
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe input.csv output.json → evaluate data
Input format:
BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber
Example (0=Neg, 1=Pos):
AXI-CTL-2026-001,85.0,4.5,65.0,95.0,1.8,2.5,0,0,3.2
— WHY IS THIS NEEDED?
Axicabtagene ciloleucel (Yescarta) is an autologous CAR-T immunotherapy for lymphoma:
• Patient's T-cells are modified with Chimeric Antigen Receptor (CAR)
• Targets CD19 antigen on tumor B-cells
• Manufacturing process is individual for each patient
• Requires strict control of viability, potency, and safety
⚠️ CRITICAL:
• Viability ≥70% — necessary for cell survival after infusion
• Dose 2–10 x 10^6 cells/kg — therapeutic window
• CAR Positive ≥50% — indicator of successful transduction and potency
• CD3+ ≥90% — confirmation of T-cell identity
• CD4/CD8 Ratio — balance of immune response
• Endotoxin ≤5 EU/mL — safety for IV administration
• Mycoplasma/Sterility — absence of contamination is mandatory
• VCN ≤10 — limitation of genotoxicity risk (insertional mutagenesis)
Key features:
• Potency assessment via CAR-positive cell percentage
• Identity (CD3+) and subset (CD4/CD8) control
• Strict microbiological criteria for live cell product
• Genetic modification safety assessment (VCN)
Critical parameters:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive: ≥50%
• CD3 Positive: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number: ≤10 copies/cell
💡 Usage tips:
1. Viability determined by flow cytometry or automated counter
2. CAR expression measured using specific anti-CAR antibodies
3. VCN determined by qPCR
4. Sterility and mycoplasma tests may take several days (rapid methods used for release)
5. Product stored cryopreserved until thawing at bedside
6. Any deviation in sterility leads to immediate batch destruction
⚠️ Note: Unlike traditional drugs, each batch is unique (autologous product). Release criteria are adapted to individual patient characteristics (dose per kg body weight). Safety is the absolute priority due to risk of cytokine release syndrome and neurotoxicity, which can be exacerbated by impurities or contamination.
input.csv
BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber AXI-CTL-2026-001,85.0,4.5,65.0,95.0,1.8,2.5,0,0,3.2 AXI-CTL-2026-002,72.0,3.0,55.0,92.0,2.1,4.0,0,0,4.5
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker — Documentation
Bilingual RU/EN URS & FS. Source:
input.csv and *.description.txt. Package folder: Biopharmaceuticals Extended QC Suite.Utility
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker
Package
Biopharmaceuticals Extended QC Suite
CSV fields
10
Interface
CSV → JSON
Utility description
Axicabtagene Ciloleucel Cell Therapy Release Quality Checker — CAR-T Therapy Release Control
ℹ️ Utility checks critical parameters for CAR-T therapy product release:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive Cells: ≥50%
• CD3+ Cells: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number (VCN): ≤10
⚠️ CRITICAL: This is a live autologous product. Contamination or low viability is unacceptable.
Low level of CAR-positive cells reduces therapy efficacy.
Usage:
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe → demo mode
AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.exe input.csv output.json → evaluate data
Input format:
BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber
Example (0=Neg, 1=Pos):
AXI-CTL-2026-001,85.0,4.5,65.0,95.0,1.8,2.5,0,0,3.2
— WHY IS THIS NEEDED?
Axicabtagene ciloleucel (Yescarta) is an autologous CAR-T immunotherapy for lymphoma:
• Patient's T-cells are modified with Chimeric Antigen Receptor (CAR)
• Targets CD19 antigen on tumor B-cells
• Manufacturing process is individual for each patient
• Requires strict control of viability, potency, and safety
⚠️ CRITICAL:
• Viability ≥70% — necessary for cell survival after infusion
• Dose 2–10 x 10^6 cells/kg — therapeutic window
• CAR Positive ≥50% — indicator of successful transduction and potency
• CD3+ ≥90% — confirmation of T-cell identity
• CD4/CD8 Ratio — balance of immune response
• Endotoxin ≤5 EU/mL — safety for IV administration
• Mycoplasma/Sterility — absence of contamination is mandatory
• VCN ≤10 — limitation of genotoxicity risk (insertional mutagenesis)
Key features:
• Potency assessment via CAR-positive cell percentage
• Identity (CD3+) and subset (CD4/CD8) control
• Strict microbiological criteria for live cell product
• Genetic modification safety assessment (VCN)
Critical parameters:
• Viability: ≥70%
• Total Viable Cells: 2–10 x 10^6/kg
• CAR Positive: ≥50%
• CD3 Positive: ≥90%
• CD4/CD8 Ratio: 0.5–5.0
• Endotoxin: ≤5 EU/mL
• Mycoplasma: Not Detected
• Sterility: Not Detected
• Vector Copy Number: ≤10 copies/cell
💡 Usage tips:
1. Viability determined by flow cytometry or automated counter
2. CAR expression measured using specific anti-CAR antibodies
3. VCN determined by qPCR
4. Sterility and mycoplasma tests may take several days (rapid methods used for release)
5. Product stored cryopreserved until thawing at bedside
6. Any deviation in sterility leads to immediate batch destruction
⚠️ Note: Unlike traditional drugs, each batch is unique (autologous product). Release criteria are adapted to individual patient characteristics (dose per kg body weight). Safety is the absolute priority due to risk of cytokine release syndrome and neurotoxicity, which can be exacerbated by impurities or contamination.URS & FS — User Requirements and Functional Specification
This document describes the controlled interface and behaviour of AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker for Axicabtagene Ciloleucel Cell Therapy Release Quality Checker.
Portal packages
Biopharmaceuticals Extended QC Suite, Biopharmaceuticals Core QC Suite, Global/API coverage extension, Immunology QC Suite, LabEx QC laboratory utilities, Lumex QC instrument utilities, World API/FDC extension
ADCAdvanced therapyBiopharmaBiopharmaExtendedBispecificCSV→JSONCellTherapyFDCImmunologyMissingAPIOncologyPlasma-derivedQCURS & FSmAbP2Domain limits and critical parameters
Key fragments from the source description are shown below. Before production use, limits must be verified against the approved specification, registration dossier and local SOPs.
- ℹ️ Utility checks critical parameters for CAR-T therapy product release:
- • Viability: ≥70%
- • CAR Positive Cells: ≥50%
- • CD3+ Cells: ≥90%
- • Endotoxin: ≤5 EU/mL
- • Sterility: Not Detected
- • Vector Copy Number (VCN): ≤10
- ⚠️ CRITICAL: This is a live autologous product. Contamination or low viability is unacceptable.
- BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber
- ⚠️ CRITICAL:
- • Viability ≥70% — necessary for cell survival after infusion
- • CAR Positive ≥50% — indicator of successful transduction and potency
- • CD3+ ≥90% — confirmation of T-cell identity
- • Endotoxin ≤5 EU/mL — safety for IV administration
- • Mycoplasma/Sterility — absence of contamination is mandatory
- • VCN ≤10 — limitation of genotoxicity risk (insertional mutagenesis)
- • Strict microbiological criteria for live cell product
- Critical parameters:
URS — User Requirements Specification
| ID | Requirement | Criticality | Acceptance criterion |
|---|---|---|---|
| URS-001 | The utility shall accept an input.csv file for Axicabtagene Ciloleucel Cell Therapy Release Quality Checker with headers defined in the data contract. | High | The file is processed without manual header editing. |
| URS-002 | The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions. | High | Identical input data, rule version and configuration produce reproducible results. |
| URS-003 | The utility shall validate mandatory fields, data types, ranges, units and domain plausibility. | High | Schema, conversion and range errors are explicitly reported. |
| URS-004 | The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs. | High | Each check has PASS/WARNING/FAIL and a clear message. |
| URS-005 | The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings. | High | JSON is suitable for LIMS/ELN/MES integration and QA/QC review. |
| URS-006 | The utility shall preserve traceability between batch/sample, input file, applied rules and final status. | High | Output contains identifiers, checked parameters and audit metadata. |
| URS-007 | The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors. | Medium | URS, FS, input/output contract and test scenarios are supplied with the utility. |
| URS-008 | The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision. | Medium | Documentation states change control and limit-verification expectations. |
input.csv contract
| # | Field | Type | Sample | Purpose |
|---|---|---|---|---|
| 1 | BatchNumber | string / controlled vocabulary | AXI-CTL-2026-001 | Batch or lot identifier used for traceability. |
| 2 | ViabilityPercent | decimal | 85.0 | Controlled input parameter for deterministic QC rules. |
| 3 | TotalViableCellsPerKg | decimal | 4.5 | Controlled input parameter for deterministic QC rules. |
| 4 | CARPositivePercent | decimal | 65.0 | Controlled input parameter for deterministic QC rules. |
| 5 | CD3PositivePercent | decimal | 95.0 | Controlled input parameter for deterministic QC rules. |
| 6 | CD4CD8Ratio | decimal | 1.8 | Controlled input parameter for deterministic QC rules. |
| 7 | EndotoxinEUPerMl | decimal | 2.5 | Microbiological/endotoxin parameter relevant to safety. |
| 8 | MycoplasmaDetected | decimal | 0 | Controlled input parameter for deterministic QC rules. |
| 9 | SterilityDetected | decimal | 0 | Microbiological/endotoxin parameter relevant to safety. |
| 10 | VectorCopyNumber | decimal | 3.2 | Controlled input parameter for deterministic QC rules. |
BatchNumber,ViabilityPercent,TotalViableCellsPerKg,CARPositivePercent,CD3PositivePercent,CD4CD8Ratio,EndotoxinEUPerMl,MycoplasmaDetected,SterilityDetected,VectorCopyNumber AXI-CTL-2026-001,85.0,4.5,65.0,95.0,1.8,2.5,0,0,3.2 AXI-CTL-2026-002,72.0,3.0,55.0,92.0,2.1,4.0,0,0,4.5
Input validation rules
| ID | Field | Rule | Criticality |
|---|---|---|---|
| VR-001 | BatchNumber | The field shall match an approved dictionary or accepted string representation. | High |
| VR-002 | ViabilityPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-003 | TotalViableCellsPerKg | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-004 | CARPositivePercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-005 | CD3PositivePercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-006 | CD4CD8Ratio | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-007 | EndotoxinEUPerMl | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-008 | MycoplasmaDetected | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-009 | SterilityDetected | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-010 | VectorCopyNumber | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
FS — Functional Specification
| ID | Function | Implementation |
|---|---|---|
| FS-001 | CLI execution | Support execution modes: demo mode without arguments and production mode input.csv output.json. |
| FS-002 | CSV import | Read input.csv in UTF-8/CSV-compatible format and validate header and expected columns. |
| FS-003 | Schema validation | Check mandatory fields, column count, unknown key fields and empty mandatory values. |
| FS-004 | Type conversion | Convert numeric, flag and text values; invalid format is recorded as a row-level error. |
| FS-005 | Domain rule engine | Apply rules for Axicabtagene Ciloleucel Cell Therapy Release Quality Checker, including critical limits from the description and approved specification. |
| FS-006 | Status aggregation | Produce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance. |
| FS-007 | JSON export | Write output.json with detailed checks, source values, warnings, failures and critical findings. |
| FS-008 | Audit support | Keep result structure suitable for review, deviation investigation and calculation reproduction. |
| FS-009 | Integration contract | Support the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review. |
| FS-010 | Fallback mapping | For a single API or modality, use this specialized utility together with applicable Lumex/LabEx instrumental checks. |
| FS-011 | Error handling | Return explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format. |
Example output.json
{
"utilityId": "axicabtagene-ciloleucel-cell-therapy-release-quality-checker",
"utilityFolder": "AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker",
"package": "Biopharmaceuticals Extended QC Suite",
"overallStatus": "PASS|WARNING|FAIL",
"sourceFile": "input.csv",
"processedAtUtc": "2026-07-02T00:00:00Z",
"checks": [
{
"parameter": "BatchNumber",
"value": "AXI-CTL-2026-001",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-001"
},
{
"parameter": "ViabilityPercent",
"value": "85.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-002"
},
{
"parameter": "TotalViableCellsPerKg",
"value": "4.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-003"
},
{
"parameter": "CARPositivePercent",
"value": "65.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-004"
},
{
"parameter": "CD3PositivePercent",
"value": "95.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-005"
},
{
"parameter": "CD4CD8Ratio",
"value": "1.8",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-006"
},
{
"parameter": "EndotoxinEUPerMl",
"value": "2.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-007"
},
{
"parameter": "MycoplasmaDetected",
"value": "0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-008"
},
{
"parameter": "SterilityDetected",
"value": "0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-009"
},
{
"parameter": "VectorCopyNumber",
"value": "3.2",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-010"
}
],
"criticalFindings": [],
"warnings": [],
"audit": {
"inputHash": "sha256:<calculated at runtime>",
"rulesVersion": "<utility executable version>",
"documentation": "AxicabtageneCiloleucel_CellTherapyReleaseQualityChecker.documentation.html"
}
}
Traceability matrix
| URS | FS | Test | Evidence |
|---|---|---|---|
| URS-001 | FS-001, FS-002 | OQ-001 | Verify execution and import of valid input.csv. |
| URS-002 | FS-005, FS-006 | OQ-004 | Repeat the same dataset and compare output.json. |
| URS-003 | FS-003, FS-004, FS-011 | OQ-002, OQ-003 | Verify missing columns and invalid types. |
| URS-004 | FS-005, FS-006 | OQ-004, PQ-001 | Verify critical deviations on real/boundary data. |
| URS-005 | FS-007, FS-009 | OQ-005 | Verify JSON schema and downstream-system suitability. |
| URS-006 | FS-008 | OQ-006 | Verify identifiers and audit metadata. |
| URS-007 | FS-008, FS-011 | IQ-001, OQ-007 | Verify documentation completeness and control evidence. |
| URS-008 | FS-005, FS-008, FS-010 | PQ-002 | Verify review workflow and no replacement of QA decision. |
IQ/OQ/PQ test scenarios
| ID | Scenario | Expected result |
|---|---|---|
| IQ-001 | Verify executable, input.csv, documentation and checksum availability. | Delivery set is complete; version is recorded. |
| OQ-001 | Valid sample row from input.csv. | PASS or acceptable WARNING according to rules. |
| OQ-002 | Remove a mandatory CSV column. | Schema error or FAIL with missing-column reference. |
| OQ-003 | Place a non-numeric value into a numeric field. | Type-conversion error with row/field reference. |
| OQ-004 | Set a critical parameter outside the limit. | FAIL and critical finding. |
| OQ-005 | Verify output.json structure. | All mandatory sections are present and JSON is valid. |
| OQ-006 | Verify batch/sample traceability. | Input and result identifiers match. |
| OQ-007 | Verify fallback/decomposition for combined APIs. | Component checks are explicitly documented. |
| PQ-001 | Verify 3–5 real user batches/samples. | Result is confirmed by QC/QA review. |
| PQ-002 | Verify deviation workflow and manual QA decision. | Utility supports review but does not replace approved decision. |
QA/QC and change control
- Do not rename columns without updating validator, documentation and test set.
- Retain input.csv, output.json, executable version and checksum.
- Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
- Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
- For combination products, document whether the specialized FDC utility or fallback component checks were used.
- The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.
Included in packages
Biopharmaceuticals Core QC Suite
Focused QC utility package for biologic products: HCP, mAbs, biosimilars, proteins/peptides, sterility, endotoxins and key release checks.
OpenBiopharmaceuticals Extended QC Suite
Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.
OpenGlobal API & Biosimilars QC Suite
Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.
OpenImmunology QC Suite
QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.
OpenWorld API Extension QC Suite
Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.
Open